Panacea Biotech, Serum join hands to take six-in-one' vaccine global
Vaccine maker Panacea Biotec has entered into a collaboration with thr Serum Institute of India to take the former's fully liquid six-in-one vaccine onto a global stage, said Rajesh Jain, Panacea's... Press Release / Media Release
Panacea Biotec Ltd. is delighted to announce the collaboration with signing of two long term agreements with Serum Institute of India Pvt. Ltd. (SII) and SII's wholly owned subsidiary, Bilthovan Biologicals B.V. (BBIO). A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Press Release / Media Release
Panacea Biotec Ltd. is delighted to announce the collaboration with signing of two long term agreements with Serum Institute of India Pvt. Ltd. (SII) and SII's wholly owned subsidiary, Bilthovan Biologicals B.V. (BBIO). A copy of the Press Release being issued to the media, etc. in this regard is enclosed for your kind reference and record please. Updates
This is with reference to the clarification sought by BSE Ltd. vide letter dated January 16, 2018 in respect of increase in volume of securities of the Company across the Exchanges. In this regard, please find enclosed herewith our clarification/reply letter on the said matter. Clarification sought from Panacea Biotec Ltd
The Exchange has sought clarification from Panacea Biotec Ltd on January 16, 2018, with reference to increase in Volume.The reply is awaited. Quarterly Report Of Investor Complaints Under Regulation 13 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Quarter Ending December 31, 2017
Pursuant to Regulation 13(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, quarterly report towards Investor Grievance for the quarter ended December 31, 2017 Updates
This is with reference to the clarification sought by BSE Ltd. vide letter dated December 08, 2017 on news item appearing in www.economictimes.com dated titled 'Panacea Biotec slides 4% after CARE downgrades firm". Please find enclosed herewith our clarification/reply letter. Clarifies on news item
With reference to news appeared in economictimes.indiatimes.com dated December 08, 2017 quoting "Panacea Biotec slides 4% after CARE downgrades firm", Panacea Biotec Ltd has submitted to BSE a copy of Clarification is enclosed. Clarification sought from Panacea Biotec Ltd
The Exchange has sought clarification from Panacea Biotec Ltd on December 08, 2017 with reference to news appeared in economictimes.indiatimes.com dated December 08, 2017 quoting "Panacea Biotec slides 4% after CARE downgrades firm". The reply is awaited. Credit Rating
Pursuant to the provisions of Regulation 30 read with Clause 3 of Part A of Schedule III of SEBI LODR Regulations, 2015, we wish to inform you that Credit Analysis & Research Ltd. (CARE) has vide its letter no. CARE/DRO/RL/2017-18/2531 dated December 07, 2017, communicated that on the basis of recent developments including operational and financial performance of the Company for financial year 2016-17 (Audited) and Q1 of financial year 2017-18 (Unaudited),...